- Losers: Marinus Pharmaceuticals (MRNS) -74% provides update on the phase 3 RAISE trial and reports preliminary first Quarter 2024 financial results.
- NextPlat Corp (NXPL) -19%.
- Neumora Therapeutics (NMRA) -17% as FDA puts Phase 1 schizophrenia study on hold.
- EZGO Technologies Ltd (EZGO) -13%.
- Monogram Orthopaedics (MGRM) -10%.
- Alterity Therapeutics Ltd (ATHE) -10%.
- Davis Commodities Ltd. (DTCK) -8%.
- Polestar Automotive Holding (PSNY) -7%.
- Torm Plc (TRMD) -6%.
- CN Energy Group (CNEY) -6%.
- Viracta Therapeutics (VIRX) -6% announces positive topline Nana-val results from Stage 1 of the NAVAL-1 trial in patients.
- Oncocyte Corporation (OCX) -6%.
- Rallybio Corp (RLYB) -6%.
- Rail Vision Ltd (RVSN) -5%.
More on Pre-market losers & stocks.
- OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript
- Monogram Orthopaedics, Inc. (MGRM) Q4 2023 Earnings Call Transcript
- Monogram Orthopaedics, Inc. 2023 Q4 - Results - Earnings Call Presentation
- NextPlat announces proposed business combination with Progressive Care
- Oncocyte stock rallies 90% post-market on Bio-Rad partnership